Annual Report Confirms Reverse Merger with 97% Dilution and Going Concern Warning

summarizeSummary

Ekso Bionics' annual report confirms a reverse merger leading to 97% dilution for current shareholders and includes a 'going concern' warning, signaling severe financial challenges and an uncertain future.

check_boxKey Events

• Reverse Merger Confirmed with Extreme Dilution

  The company confirmed a Contribution and Exchange Agreement (dated February 15, 2026) with Applied Digital Cloud Corporation, where the contributor will own approximately 97% of the combined company, ChronoScale Corporation, upon closing in Q2 2026. This represents extreme dilution for existing shareholders.

• Substantial Doubt About Going Concern

  Both management and the independent auditor expressed 'substantial doubt' about the company's ability to continue as a going concern for the next 12 months, citing significant operating losses and negative cash flows.

• Continued Financial Decline

  For the year ended December 31, 2025, revenue decreased by $5.1 million (29%) to $12.8 million, and loss from operations increased by 27% to $13.3 million, indicating worsening financial performance.

• Recent Dilutive Capital Raises

  The company raised approximately $5.3 million from a private placement of convertible preferred stock and warrants (January 2026), $3.2 million from a registered direct offering (October 2025), and $3.85 million from an inducement warrant transaction (March 2025), alongside $0.9 million from ATM sales in 2025, all contributing to significant shareholder dilution.

auto_awesomeAnalysis

This annual report provides a comprehensive financial overview, confirming the previously announced reverse merger with Applied Digital Cloud Corporation. The transaction, expected to close in Q2 2026, will result in existing shareholders owning only approximately 3% of the combined entity, representing extreme dilution. The filing also includes a critical 'going concern' warning from both management and the auditor, indicating substantial doubt about the company's ability to continue operations for the next 12 months without additional financing. This financial distress is underscored by a 29% decrease in revenue and a 27% increase in operating losses for 2025, alongside significant cash burn. The company has relied heavily on dilutive capital raises, including a $5.3 million private placement and other offerings, to maintain liquidity, but these are insufficient to alleviate long-term solvency concerns without the merger or further capital. The report highlights the precarious financial position and the transformative, highly dilutive nature of the pending merger.